Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 3 1

Status

Withdrawn 1Unknown 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Tumor-Agnostic 2Genitourinary 2Gynecologic 1Breast 1

Conditions

Prostatic Neoplasms 75Neoplasm Metastasis 8Prostatic Neoplasms, Castration-Resistant 5Neoplasms 5Carcinoma, Non-Small-Cell Lung 4Metastatic Castration-Resistant Prostate Cancer 3Urogenital Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Primary Myelofibrosis 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Multiple Myeloma 2Metastatic Castration-resistant Prostate Cancer 2Melanoma 2Lymphoma, Non-Hodgkin 2Colorectal Neoplasms 2Castration-resistant Prostate Cancer 2Bulbo-Spinal Atrophy, X-Linked 2Breast Neoplasms 2Bites and Stings 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Solid Tumours 1Salivary Gland Neoplasms 1Prostatic Diseases 1Prostate Cancer Metastatic Disease 1

Interventions

pembrolizumab 180Gemcitabine 168Paclitaxel 150Carboplatin 134Bevacizumab 126Cisplatin 113Docetaxel 112Cyclophosphamide 109Exercise 97Nivolumab 92Fluorouracil 88Capecitabine 85Dexamethasone 81Irinotecan 74Radiotherapy 68Oxaliplatin 68Pemetrexed 66Standard of Care 64Leucovorin 63Cetuximab 59Sorafenib 53Erlotinib Hydrochloride 53Drug Therapy 53Blood Specimen Collection 52Doxorubicin 50trametinib 47atezolizumab 47Ipilimumab 47Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Neoplasms × abiraterone × Clear all
NCT06691984 2026-05-15

Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)

Amgen

Phase 3 Active not recruiting
707 enrolled
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT03480646 2025-10-29

ProSTAR: A Study Evaluating CPI-1205 in Patients With Metastatic Castration Resistant Prostate Cancer

Constellation Pharmaceuticals

Phase 1/2 Completed
175 enrolled 23 charts
Tumor-Agnostic

Neoplasms

NCT04726332 2024-05-14

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Exelixis

Phase 1 Terminated
52 enrolled
BreastGynecologic

Carcinoma, Ovarian Epithelial, Neoplasms, Triple Negative Breast Neoplasms

NCT02380313 2016-10-06

Dose-Finding Study of Afuresertib Administered in Combination With Either Enzalutamide or Aibraterone

GlaxoSmithKline

Phase 1 Withdrawn
Tumor-Agnostic

Neoplasms

NCT02049190 2015-06-24

Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer

Arno Therapeutics

Phase 1/2 Unknown
75 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡